FDA to Review Etrasimod NDA for Ulcerative Colitis - MPR The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for etrasimod for the treatment of patients with moderately to severely active ulcerative colitis (UC)
NATAZIA Prescription Dosage Information - MPR NATAZIA prescription and dosage information for physicians and health care professionals Pharmacology, adverse reactions, warnings, and NATAZIAside effects
EndoBarrier Device Significantly Reduced HbA1c, Weight - MPR At the 2014 American Diabetes Association Scientific Sessions, GI Dynamics presented study findings that demonstrated the acute effects of EndoBarrier Therapy on glycemic control, its ability to
Antibody Oligonucleotide Conjugate Fast Tracked for . . . - MPR AOC 1020 is designed to reduce the expression of DUX4 mRNA and DUX4 protein in muscles The Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1020 for the treatment of
Preferential Use of Lactated Ringer vs Saline May Reduce . . . Preferential use of balanced crystalloids such as lactated Ringer vs saline solution results in reduced risk for major adverse kidney events (MAKEs), according to new findings from a real-world study